EHT401

EHT401 is an investigational therapeutic candidate being developed by Euhearing Therapeutics for the treatment of congenital monogenic hearing loss. It is part of the company's pipeline of genetic medicines designed to address hereditary forms of deafness. Currently in the early research or preclinical stage, EHT401 is intended to target a specific genetic mutation that causes hearing impairment. While the exact molecular target and mechanism have not been publicly disclosed, the candidate likely utilizes a gene therapy approach, consistent with the developer's focus on restoring auditory function through genetic intervention in the inner ear.